ArticleEndocrine1995
Islet expression of Rhombotin and Isl-1 suggests cell type specific exposure of LIM-domain epitopes.
Article in Endocrine, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Whole-Genome Methylation Sequencing Analysis and Functional Verification of LIM-Homeobox Family Genes in Cervical Cancer.International journal of general medicine · 2025Article
- Effect ofTranslational cancer research · 2021Article
- Serine and threonine phosphorylation of the paxillin LIM domains regulates paxillin focal adhesion localization and cell adhesion to fibronectin.Molecular biology of the cell · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The homeodomain protein Isl-1 and the proto-oncogene Rhombotin (a LIM-only protein), share a double zinc-binding LIM domain and have both been implicated in neural and possibly endocrine development. Isl-1 is expressed in all endocrine cell-types of the islet of Langerhans while Rhombotin mRNA expression was reported in rat insulinoma cells. We have cloned and sequenced Rhombotin cDNA from rat insulinoma (99.4% identical to human and mouse sequences) and demonstrate that it is expressed in normal islets, intestinal tissue, and testis, in addition to the brain; but absent in all other organs tested. Rhombotin mRNA is expressed in phenotypically distinct islet tumours (α-, β, and δ-tumours) at levels comparable to that of normal islets. Antisera raised against two distinct epitopes contained within a short synthetic peptide representing part of the N-terminal LIM domain of Rhombotin surprisingly stain α- and δ-cells, respectively, on sections of rat pancreas. Rhombotin is undetectable by immunocytochemistry using LIM-domain antisera on intact monolayer islet tumor cells or transfected fibroblasts while readily detectable when equipped with a FLAG epitope, as detected with FLAG antiserum. In contrast, recombinant FLAG-Rhombotin is efficiently recognised by Western blotting or immunoprecipitation with all LIM-specific antisera. Almost identical results were obtained with LIM-specific versus homeodomain/C-terminal Isl-1 antisera staining α-cell cytoplasm or all islet nuclei, respectively. We conclude that Rhombotin in addition to Isl-1 is expressed in the islet of Langerhans and propose that the differential staining patterns obtained with antisera towards the LIM domains versus flanking epitopes of both proteins reflect (1) cell-specific protein-protein interactions of these domains or, alternatively, (2) islet cell type specific expression of novel homologous LIM domain proteins.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.